Phase 1 Rectal Cancer Clinical Trials

127 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 120 of 127 trials

Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 1

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled7 locationsNCT06459869
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Colorectal, CancerColon CancerCRC+4 more
Cartography Biosciences80 enrolled8 locationsNCT07321106
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.448 enrolled12 locationsNCT06835569
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 1

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
Hoffmann-La Roche180 enrolled1 locationNCT07416552
Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

MelanomaNon-small Cell Lung CancerThyroid Cancer+2 more
Pfizer267 enrolled40 locationsNCT05355701
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1Phase 2

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Recurrent Colorectal CarcinomaLocally Advanced Colorectal CarcinomaStage III Colorectal Cancer
Roswell Park Cancer Institute21 enrolled1 locationNCT06307548
Recruiting
Phase 1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)24 enrolled13 locationsNCT06696768
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541